{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:17:38Z","timestamp":1781176658602,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.revmed.2016.09.010","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T14:01:46Z","timestamp":1478700106000},"page":"160-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["\u00c9v\u00e9nements infectieux survenus au cours des maladies auto-immunes trait\u00e9es par rituximab\u00a0: \u00e0 partir d\u2019une \u00e9tude r\u00e9trospective de 93\u00a0cas"],"prefix":"10.1016","volume":"38","author":[{"given":"M.","family":"Catroux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lauda-Maillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-C.","family":"De Boisgrollier de Ruolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cazenave-Roblot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Roblot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Souchaud-Debouverie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2016.09.010_bib0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.23171","article-title":"The effects of rituximab on immunocompetency in patients with autoimmune disease","volume":"58","author":"Looney","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.09.010_bib0140","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-CD20\u00a0monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.revmed.2016.09.010_bib0145","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.lpm.2009.02.002","article-title":"Rituximab et traitement des maladies auto-immunes et inflammatoires syst\u00e9miques","volume":"38","author":"Bussone","year":"2009","journal-title":"Presse Med"},{"key":"10.1016\/j.revmed.2016.09.010_bib0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.revmed.2016.09.010_bib0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.09.010_bib0160","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-Cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.09.010_bib0165","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20\u00a0monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2016.09.010_bib0170","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","article-title":"Rituximab in idiopathic membranous nephropathy: a one-year prospective study","volume":"14","author":"Ruggenenti","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2016.09.010_bib0175","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1212\/01.wnl.0000201193.00382.b3","article-title":"High-dose rituximab and anti-MAG-associated polyneuropathy","volume":"66","author":"Renaud","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2016.09.010_bib0180","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"issue":"Suppl. 4","key":"10.1016\/j.revmed.2016.09.010_bib0185","doi-asserted-by":"crossref","first-page":"iv55","DOI":"10.1136\/ard.2005.042648","article-title":"Update on rituximab","volume":"64","author":"Eisenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.09.010_bib0190","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2005.08.006","article-title":"The therapeutic potential of anti-CD20 \u201cwhat do B-cells do?\u201d","volume":"117","author":"Eisenberg","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.revmed.2016.09.010_bib0195","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.09.010_bib0200","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.09.010_bib0205","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.09.010_bib0210","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.09.010_bib0215","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jbspin.2015.05.012","article-title":"Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: an observational study","volume":"83","author":"Lazarou","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2016.09.010_bib0220","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.revmed.2015.06.005","article-title":"Le rituximab dans la vraie vie\u00a0: revue d\u2019utilisation du rituximab de 2010\u00a0\u00e0 2013\u00a0au CHU de Saint-\u00c9tienne","volume":"36","author":"Reynaud","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2016.09.010_bib0225","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.09.010_bib0230","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","article-title":"Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)","volume":"74","author":"Bingham","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.09.010_bib0235","unstructured":"Haut Conseil de la Sant\u00e9 Publique. Vaccinations des personnes immunod\u00e9prim\u00e9es ou aspl\u00e9niques. Recommandations [Internet]. Disponible sur\u00a0: http:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=322 [consult\u00e9 le 21\u00a0f\u00e9vrier 2016]."},{"key":"10.1016\/j.revmed.2016.09.010_bib0240","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard.2008.088302","article-title":"Risk factors for major infections in Wegener granulomatosis: analysis of 113\u00a0patients","volume":"68","author":"Charlier","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.09.010_bib0245","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.09.010_bib0250","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ki.2010.489","article-title":"ANCA-associated glomerulonephritis in the very elderly","volume":"79","author":"Bomback","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2016.09.010_bib0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.semarthrit.2015.02.005","article-title":"Rituximab for remission induction in elderly patients with ANCA-associated vasculitis","volume":"45","author":"Timlin","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.09.010_bib0130","unstructured":"Club rhumatisme et inflammations. Bilan pr\u00e9-th\u00e9rapeutique initial [Internet]. Disponible sur\u00a0: http:\/\/www.cri-net.com\/ckfinder\/userfiles\/files\/fiches-pratiques\/rituximab\/1_Bilan_Pre-therapeutique_VDEF.pdf [consult\u00e9 le 23\u00a0f\u00e9vrier 2016]."}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866316305495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866316305495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:36:52Z","timestamp":1759336612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866316305495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0248866316305495"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2016.09.010","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9v\u00e9nements infectieux survenus au cours des maladies auto-immunes trait\u00e9es par rituximab\u00a0: \u00e0 partir d\u2019une \u00e9tude r\u00e9trospective de 93\u00a0cas","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2016.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}